Clinical trials: Borderline Resectable/Unresectable Pancreatic Cancer
- Condition Borderline Resectable/Unresectable Pancreatic Cancer
- Funder type Industry (pharma, biotech, devices)
SBRT, Borderline Resectable Pancreatic Cancer
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline…
- Conditions
- SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT04698915
- Testing
- Drug GC4711
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 177 people
- Sponsor
- Galera Therapeutics, Inc.